Rabbit Polyclonal CCND3 Antibody

+ +

•  

   
     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P03861(CCND3 Antibody) at dilution 1/40. (Original magnification: ×200)    

•  

   
     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P03861(CCND3 Antibody) at dilution 1/40. (Original magnification: ×200)    

The CCND3 antibody is a crucial tool in studying cyclin D3. a protein encoded by the CCND3 gene, which plays a pivotal role in cell cycle regulation. Cyclin D3 belongs to the D-type cyclin family (D1. D2. D3) and forms complexes with cyclin-dependent kinases (CDK4/6) to drive cell cycle progression from the G1 to S phase by phosphorylating the retinoblastoma (Rb) protein. This phosphorylation releases transcription factors critical for DNA replication. Dysregulation of CCND3 is implicated in various cancers, including lymphomas, leukemias, and solid tumors, where its overexpression or amplification can lead to uncontrolled proliferation. Conversely, reduced CCND3 expression is linked to cell cycle arrest or differentiation.

The CCND3 antibody is widely used in research applications such as Western blotting, immunohistochemistry (IHC), and flow cytometry to detect protein expression levels, localization, and interactions. It aids in elucidating mechanisms of tumorigenesis, drug resistance, and therapeutic targeting, particularly in cancers with cyclin-CDK pathway abnormalities. Specificity and validation (e.g., knockout controls) are essential to ensure accurate detection, as cross-reactivity with other D-type cyclins may occur. Commercial CCND3 antibodies are typically raised against peptide sequences unique to the human CCND3 protein, with reactivity across species like mouse and rat. Its role in biomarker studies and preclinical models underscores its importance in both basic and translational cancer research.